Slide 1: Q4FY26 Result Presentation filing letter to exchanges
Date: 21st May 2026 To, National Stock Exchange of India Limited BSE Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Bandra Kurla Dalal Street, Mumbai – 400001 Complex, Bandra (E), Mumbai – 400051 Scrip Code: 544619 Scrip Symbol- SUDEEPPHRM Sub: Q4FY26 - Result Presentation Ref: Regul
Slide 2: Sudeep Pharma Limited Investor Presentation May 2026
Sudeep Pharma Limited Investor Presentation May 2026
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Sudeep Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securit
Slide 4: Q4 & FY26 Performance Highlights
Q4 & FY26 Performance Highlights
Slide 5: MD's Message
MD’s Message “We are pleased to report another strong year for Sudeep Pharma, marked by several strategic milestones and our highest-ever revenue of Rs. 642.3 crore. FY26 was a transformative year for the Company, highlighted by the successful listing of Sudeep Pharma Limited, providing us with a st
Slide 6: Q4 & FY26 Performance Highlights
Q4 & FY26 Performance Highlights Revenue from Operations EBITDA & Margin % PAT & Margin % Rs. Cr. Rs. Cr. Rs. Cr. 37.3% 34.3% 37.8% 34.6% 28.0% 26.6% 27.6% 27.1% +28% +17% +26% 642.3 221.9 174.3 502.0 190.0 138.7 +16% +6% +10% 157.5 182.3 58.8 62.6 44.2 48.5 Q4FY25 Q4FY26* FY25 FY26* Q4FY25 Q4FY26*
Slide 7: Q4 & FY26 Key Highlights
Q4 & FY26 Key Highlights • Revenue from operations for the Q4FY26 stood at Rs. 182.3 Crs, registering a growth of 16% YoY. • The Company has appointed a new business head for NSS, and the integration process is progressing smoothly with encouraging operational and customer synergies. • During the qu
Slide 8: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (Rs. Crs) Q4FY26* Q4FY25 YoY FY26* FY25 YoY Revenue from Operations 182.3 157.5 16% 642.3 502.0 28% Cost of materials consumed 63.9 59.8 227.3 164.8 Employee Expenses 10.5 10.9 51.9 38.3 Other Expenses 45.4 28.1 141.2 108.9 EBITDA 62.6 58.8 6% 221.9 1
Slide 9: Consolidated Balance Sheet Statement
Consolidated Balance Sheet Statement Assets (Rs. Crs) Mar-26 Mar-25 Equity & Liabilities (Rs. Crs) Mar-26 Mar-25 Non - Current Assets 550.9 293.1 Total Equity 898.1 493.1 Property, plant and equipment 224.0 177.1 11.3 Equity share capital 9.7 Capital work-in-progress 178.4 88.2 Instruments entirely
Slide 10: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (Rs. Crs) Mar-26* Mar-25 Net Profit Before Tax 228.1 182.8 Adjustments for: Non -Cash Items / Other Investment or Financial Items 9.0 15.5 Operating profit before working capital changes 237.1 198.3 Changes in working capital -112.1 -109.0 Cash generated
Slide 11: Key Factors Driving Higher Working Capital Days
Key Factors Driving Higher Working Capital Days Net Working Capital Days# ▪ Recently established warehousing operations in the U.S. and Europe, with inventory 213 turnover expected to commence over the next 3-4 months few quarters 184 ▪ NSS inventory has been consolidated as of date, whereas the cor
Slide 12: Battery Materials - Ground Breaking Ceremony of Land in Dahej, Gujarat
Battery Materials - Ground Breaking Ceremony of Land in Dahej, Gujarat Successfully conducted the groundbreaking ceremony for Battery Materials Plant at Dahej on January 23, 2026. Setting up plant at Dahej, Gujarat • Project cost: Appx. Rs 300 crores • Expect completion by early CY27 • Mode of Finan
Slide 13: Capacity Expansion & Strategic Validation
Capacity Expansion & Strategic Validation Strategic Positioning: Emerging as a premier reliable non-Chinese supplier for battery-grade iron phosphate PCAM. Manufacturing Scale: Global Presence in Dominant Battery Markets Phase 1: 42 28 Customers across South Korea, Japan, Indonesia, Europe, USA, & A
Slide 14: Company Overview
p Pharma Limited s Sudee Company Overview
Slide 15: Sudeep Pharma at a Glance
Sudeep Pharma at a Glance Founded in 1989, 3+ decades of experience in 35 Years of Expertise in vitamins & mineral chemistries* 5 Manufacturing Sites ^ Specialty Chemistries Metric Tones (“MT”) Fortune 500 Companies1 Leading player in the Excipients & 14 as customers ~1,23,000 + Annual Manufacturing
Slide 16: Our Journey from Pharma Excipients to Specialty Ingredients Manufacturer
Our Journey from Pharma Excipients to Specialty Ingredients Manufacturer 2025 2024 2021–2023 2015–2022 Strategic 1989 Acquisitions & Diversification & IPO Readiness Ownership Innovation and Consolidation Global Portfolio Foundation & Partnerships & Expansion Early Market Entry Operations 2024 2025 2
Slide 17: Corporate Structure
Corporate Structure Sudeep Pharma Limited (Holding) Sudeep Nutrition Private Ltd. Sudeep Pharma USA Inc. Sudeep Pharma B.V. Sudeep Advanced Materials (Wholly Owned Subsidiary) (Wholly Owned Subsidiary) (Wholly Owned Subsidiary) (Wholly Owned Subsidiary) 85% Ownership 16
Slide 18: One of the World's Leading and Trusted Manufacturer
One of the World’s Leading and Trusted Manufacturer The Start At Present 2020 2021 2023 2024 2025 Ireland Manufacturing 5 Site¹ Manufacturing Sites^ Europe Sales Office – The HQ - Vadodara, Netherlands² Gujarat³ 100+ Products 4 Manufacturing USA Sales Office - New Sites, India ⁴ Jersey² Mumbai Offic
Slide 19: Strengths - Core Competencies and USP's
Strengths - Core Competencies and USP’s Innovation Engineered Through Proprietary Technologies Leadership in High Barrier Industry, Diversified Product Portfolio 6 indigenously developed technologies 100+ Products across different verticals Encapsulation Spray Drying Granulation Liposomal Trituratio
Slide 20: Key Value Propositions
Key Value Propositions 1. Market Leadership with 6. Distinguished global customer Diversified Product Portfolio base with long standing relationships with Key Customers 2. High Entry Barriers 7. Proven Credentials and Leading Accolades Key 3. Well-Equipped & Regulatory Compliant Manufacturing Value
Slide 21: 1. Market Leadership with Diversified Product Portfolio
1. Market Leadership with Diversified Product Portfolio Delivering Products that Matter Pharmaceutical, Food & Nutrition Speciality Ingredients Battery Materials Mineral Micro-nutrient Liposomal Fillers Ingredients Battery-Grade Iron Phosphate* Fortificants Premixes pCAM for LFP (Lithium Iron Phosph
Slide 22: 2. High Entry Barriers
2. High Entry Barriers Cost Split of a Tablet Composition split of a Tablet ~5% Excipients ~95% API ~95% Excipients ~5% API Low Cost but High Functionality Disintegration & Tablet Performance^ Stability of Tablet^ Dissolution^ Product Range Tailored to Meet the Precise Needs of Customers in a High B
Slide 23: 3. Well-Equipped & Regulatory Compliant Manufacturing Facilities
3. Well-Equipped & Regulatory Compliant Manufacturing Facilities Unit I – Nandesari Unit II – Nandesari 12 Set Up 1989 Set Up 2011 Production Lines Calcium Carbonate - Powder, Tricalcium Phosphate, Dicalcium Products Oxides, Carbonates, Sulphates Products Phosphate, Iron Phosphate, Magnesium Stearat
Slide 24: 4. Proprietary Technologies
4. Proprietary Technologies Encapsulation Spray Drying Granulation Blending Liposomal Preparation Trituration Expertise In: Extending Product Shelf-life Target, Controlled and Sustained Release Address Taste and Odor Challenges Particle Engineering Enhance Ingredient Bio-Availability Improved Produc
Slide 25: 5. Strong Research & Development Capabilities
5. Strong Research & Development Capabilities R&D Expenses (% of Revenue from Operations) 1.96% 1.71% 41 R&D Personnel 6 Proprietary Technologies 1.66% 0.91% FY23 FY24 FY25 FY26 R&D Initiatives Assist in^ : • Extending Product Shelf-Life & Vitality • Ensuring Targeted release of excipients • Underta
Slide 26: 6. Distinguished global customer base with long standing relationships
6. Distinguished global customer base with long standing relationships with Key Customers 14 ^ 1,120+ 8% Global Fortune 500 Single Largest Customers served^ companies as customers^ Customer ~100 Countries Global presence ^ ^ 40+ 25% 32% ~7 Years Top 10 Blue-chip multinational Top 5 Customers Avg. te
Slide 27: 7. Proven Credentials and Leading Accolades
7. Proven Credentials and Leading Accolades Key Awards Key Certifications FRK Manufacturing Customer Centric Excellence Business Partner Award Award By Millers for By Abbott Nutrition Suppliers Excellence in Summit 2023 Innovative Award Ingredients Manufacturing By Herbalife By Nutrition ASSOCHAM Gl
Slide 28: 8. Experienced Board and Senior Management Team
8. Experienced Board and Senior Management Team Promoters & Directors Board Members Mr. Ajay Kandelkar- Director of Operations Dairy technology from Dr. Panjabrao Deshmukh KV 23 years of experience in production & operations Past Association - Drytech, Taiyo-Kagaku Independent Director Mr. Samaresh
Slide 29: 9. Healthy Improvement in Performance with Disciplined Balance Sheet
9. Healthy Improvement in Performance with Disciplined Balance Sheet Revenue from Operations EBITDA & Margin % Rs. Cr. Rs. Cr. 20.8% 39.6% 37.8% 34.6% +14% 642.3 502.0 +36% 428.7 459.3 221.9 181.7 190.0 89.1 FY23 FY24 FY25 FY26* FY23 FY24 FY25 FY26* PAT & Margin % Net Debt & Net Debt / Equity (x) Rs
Slide 30: 10. Backed by Healthy Growth in End User Industries
10. Backed by Healthy Growth in End User Industries Battery Speciality Ingredients Pharmaceutical Excipients Chemicals Food Nutritional Encapsulated Micronutrient Granulated Global India Global Market Ingredients Ingredients Ingredients Ingredients Ingredients Excipients Excipients Market Size USD 8
Slide 31: Growth Levers
n ro o > ® al ra s S ) = 10)
Slide 32: Key Capacity Expansion
Key Capacity Expansion Capacity Visibility (in MT)* FY26 Key Segments FY25 FY27e FY28e FY29e FY30e Existing 1) Pharma, Food & Nutrition 35,000 35,000 86,200 86,200 86,200 86,200 - Greenfield Project Addition 51,200 2) Speciality Ingredients 30,000 37,500 37,500 37,500 37,500 37,500 - NSS Capacity Ad
Slide 33: 1. Organic Growth – Upcoming Greenfield Expansion
1. Organic Growth – Upcoming Greenfield Expansion Upcoming Greenfield at Nandesari, Gujarat Location Total Capex Capacity Nandesari GIDC, Vadodara Gujarat ~ 150 Crores INR 51,200 MT Annually Focused Segment Mode of Financing Commissioning Status Pharmaceutical Excipients, Actives and Internal Accrua
Slide 34: 2. Organic Growth – Leveraging Mineral Chemistry Expertise for Battery Materials
2. Organic Growth – Leveraging Mineral Chemistry Expertise for Battery Materials Key Pillar Our Advantage Leveraging Decade of expertise in Iron Phosphate FEOC-Compliant Supply Fully aligned with FEOC compliance norms, helping customers meet regulations Chain under the US IRA & EU Critical Raw Mater
Slide 35: 3. Inorganic Growth – Vitamin & Mineral Blends Business Acquisition
3. Inorganic Growth – Vitamin & Mineral Blends Business Acquisition Integrate Recently Acquired Entities & Continue Evaluating Inorganic Growth Opportunities Acquired 85.00% Engaged in business of manufacturing of vitamin & mineral blends in form May 2025 of dry blends, water soluble blends, oil sol
Slide 36: Historical Financial Statements
Historical Financial Statements
Slide 37: Historical Profit & Loss Statement
Historical Profit & Loss Statement Particulars (Rs. Crs) FY26* FY25 FY24 FY23 Revenue from Operations 642.3 502.0 459.3 428.7 Cost of materials consumed 227.3 164.8 165.3 182.5 Employee Expenses 51.9 38.3 29.4 66.1 Other Expenses 141.2 108.9 82.9 91.1 EBITDA 221.9 190.0 181.7 89.1 EBITDA Margin (%)
Slide 38: Historical Balance Sheet Statement
Historical Balance Sheet Statement Assets (Rs. Crs) Mar-26* Mar-25 Mar-24 Mar-23 Equity & Liabilities (Rs. Crs) Mar-26* Mar-25 Mar-24 Mar-23 Non - Current Assets 550.9 293.1 238.5 190.1 Total Equity 898.1 493.1 356.0 223.3 Property, plant and equipment 224.0 177.1 167.0 149.4 Equity share capital 11
Slide 39: Historical Cash Flow Statement
Historical Cash Flow Statement Particulars (Rs. Crs) Mar-26* Mar-25 Mar-24 Mar-23 Net Profit Before Tax 228.1 182.8 174.8 86.0 Adjustments for: Non -Cash Items / Other Investment or Financial Items 9.0 15.5 13.5 17.9 Operating profit before working capital changes 237.1 198.3 188.3 103.9 Changes in
Slide 40: Utilization of Net Proceeds
Utilization of Net Proceeds Particulars Original Amount Utilized in FY26 Amount Un-utilized Capital expenditure towards procurement of machinery for our production line located at Nandesari Facility I 75.8 - 75.8 General Corporate Purposes 12.5 12.5 - Total 88.3 12.5 75.8 39
Slide 41: Thank You!
Thank You! Company Details: Investor Relations Advisor : Strategic Growth Advisors Pvt. Ltd. Sudeep Pharma Ltd. CIN - U74140MH2010PTC204285 CIN – L24231GJ1989PLC013141 Mr. Shrikant Sangani / Ms. Shaily Patwa Ms. Dimple Mehta – Company Secretary Email - shrikant.sangani@sgapl.net / shaily.p@sgapl.net